Back to top
more

Oxford Immunotec Global PLC (OXFD)

(Delayed Data from NSDQ)

$16.54 USD

16.54
41,942

+0.35 (2.16%)

Updated May 3, 2019 04:00 PM ET

After-Market: $16.55 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Oxford Immunotec (OXFD) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

by Zacks Equity Research

Oxford Immunotec (OXFD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Oxford Immunotec (OXFD) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Oxford Immunotec (OXFD) delivered earnings and revenue surprises of 50.00% and 4.61%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Oxford Immunotec (OXFD) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Oxford Immunotec (OXFD) delivered earnings and revenue surprises of -428.57% and -4.19%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Oxford Immunotec (OXFD) Q2 Earnings Expected to Decline

by Zacks Equity Research

Oxford Immunotec (OXFD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Oxford Immunotec (OXFD) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Oxford Immunotec (OXFD) delivered earnings and revenue surprises of -185.71% and -1.41%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Oxford Immunotec (OXFD) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Oxford Immunotec (OXFD) delivered earnings and revenue surprises of 45.45% and 4.80%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Oxford Immunotec Global Stock: Moving Average Crossover Alert

by Zacks Equity Research

Oxford Immunotec Global is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

MEDNAX (MD) Ties Up With Homestead to Expand in Florida

by Zacks Equity Research

MEDNAX (MD) collaborates with Associated Pediatricians of Homestead to provide clinical services and expand presence in Florida.

Oxford Immunotec (OXFD) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Oxford Immunotec (OXFD) delivered earnings and revenue surprises of 180.00% and 4.17%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Will Oxford Immunotec (OXFD) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Oxford Immunotec (OXFD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Oxford Immunotec (OXFD) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Oxford Immunotec (OXFD) delivered earnings and revenue surprises of 140.00% and 0.76%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Will Oxford Immunotec (OXFD) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Oxford Immunotec (OXFD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Varian (VAR) Installs ProBeam Compact in Thailand's Hospital

by Zacks Equity Research

Varian (VAR) gains from a slew of recent developments in its Proton Therapy platform.

Varian (VAR) to Boost Cancer Treatment With New Partnership

by Zacks Equity Research

Varian (VAR) expects to enhance cancer care with the new collaboration with IAEA, which is likely to drive Varian's core Oncology business.

Here's Why You Should Invest in Wright Medical Stock Now

by Zacks Equity Research

Wright Medical (WMGI) continues to benefit from strong international sales, new product launches and solid prospects in the global Orthopedic space.

Here's Why You Should Invest in CONMED (CNMD) Stock Now

by Zacks Equity Research

CONMED (CNMD) continues to benefit from robust international sales, broad product portfolio and persistent focus on R&D.

Luminex (LMNX) Presents ARIES MRSA Assay to FDA for Clearance

by Zacks Equity Research

Luminex (LMNX) submits the ARIES MRSA assay to the FDA for clearance. The company's ARIES system will get a substantial boost once the FDA clearance is through.

Here's Why You Should Hold on to Nevro (NVRO) Stock Now

by Zacks Equity Research

Nevro (NVRO) is gaining traction from a fortified international footprint and solid prospects in the SCS market. However, severe rivalry is a lingering woe.

Here's Why You Should Retain Cardinal Health (CAH) Stock

by Zacks Equity Research

Cardinal Health (CAH) is gaining from diversified product portfolio and robust pharmaceutical segment. However, integration risks remain a concern.

Here's Why You Should Hold on to Surmodics (SRDX) Stock Now

by Zacks Equity Research

Surmodics (SRDX) is gaining from consistent growth In Vitro Diagnostics (IVD) unit and persistent efforts to boost R&D functionalities.

Here's Why You Should Hold on to McKesson (MCK) Stock Now

by Zacks Equity Research

McKesson (MCK) is gaining from strong segmental performance and solid prospects in the pharmaceutical and medical supplies distribution market.

Here's Why You Should Retain Allscripts (MDRX) Stock Now

by Zacks Equity Research

Allscripts (MDRX) is gaining steadily from strategic acquisitions and solid prospects in Sunrise EHR platform. However, integration risks remain a woe.

Here's Why You Should Invest in Cooper Companies Stock Now

by Zacks Equity Research

Cooper Companies (COO) is gaining traction from expansion in international markets, robust product portfolio across segments and prudent acquisitions.

Here's Why You Should Hold on to Stryker (SYK) Stock Now

by Zacks Equity Research

Stryker (SYK) is gaining steadily from strong international growth and robust product portfolio. However, unfavorable pricing environment remains a woe.

    AMN Healthcare (AMN) Closes Advanced Medical Acquisition

    by Zacks Equity Research

    AMN Healthcare (AMN) completes Advanced Medical buyout that will help the former to boost offerings in some of the fastest growing and very important care settings.